Revvity (NYSE:RVTY) Hits New 1-Year High - Here's What Happened

Key Points

• Revvity shares reached a new 52-week high of $166.25, while the stock’s average analyst rating remained “Hold” with an average price target of $116.57.
• The company beat quarterly expectations, reporting adjusted EPS of $1.41 versus the $1.21 consensus and revenue of $729.69 million, though revenue declined 1.3% year over year.
• Institutional ownership stands at 86.65%, with several major investors adding shares, while insiders sold a combined 9,130 shares worth approximately $1.29 million over the past three months.

Revvity Inc. (NYSE:RVTY - Get Free Report)'s stock price hit a new 52-week high on Wednesday. The stock traded as high as $166.25 and last traded at $153.3340, with a volume of 2678173 shares trading hands. The stock had previously closed at $157.36.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Sanford C. Bernstein assumed coverage on shares of Revvity in a report on Friday, June 26th. They set a "market perform" rating and a $115.00 price target for the company. Zacks Research raised Revvity from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 4th. Weiss Ratings upgraded Revvity from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, July 30th. Royal Bank Of Canada started coverage on Revvity in a research note on Tuesday, September 1st. They set a "sector perform" rating and a $135.00 target price for the company. Finally, TD Cowen reissued a "buy" rating on shares of Revvity in a report on Wednesday, July 15th. Five analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $116.57.

Revvity Price Performance

The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. The stock's fifty day moving average price is $130.08 and its 200-day moving average price is $109.82. The firm has a market cap of $17.11 billion, a PE ratio of 73.02, a P/E/G ratio of 2.86 and a beta of 1.06.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The firm had revenue of $729.69 million for the quarter, compared to the consensus estimate of $702.96 million. During the same quarter in the previous year, the firm earned $1.18 earnings per share. The firm's revenue was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts forecast that Revvity Inc. will post 5.36 EPS for the current fiscal year.

Revvity Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity's dividend payout ratio (DPR) is presently 13.33%.

Insider Activity at Revvity

In other news, insider Tajinder Vohra sold 7,330 shares of the business's stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the sale, the insider owned 6,635 shares of the company's stock, valued at $934,738.80. The trade was a 52.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Maxwell Krakowiak sold 1,631 shares of the company's stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the completion of the sale, the insider owned 14,781 shares in the company, valued at approximately $2,136,297.93. This represents a 9.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 9,130 shares of company stock worth $1,290,745 in the last three months. Corporate insiders own 0.85% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Public Employees Retirement System of Ohio purchased a new stake in shares of Revvity in the second quarter valued at about $3,845,000. The Manufacturers Life Insurance Company increased its stake in shares of Revvity by 5.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 368,938 shares of the company's stock worth $41,048,000 after purchasing an additional 20,278 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Revvity by 10,653.8% during the 2nd quarter. Wellington Management Group LLP now owns 865,575 shares of the company's stock worth $96,304,000 after purchasing an additional 857,526 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Revvity during the 2nd quarter worth approximately $78,766,000. Finally, Tocqueville Asset Management L.P. acquired a new position in shares of Revvity during the 2nd quarter worth approximately $4,791,000. Hedge funds and other institutional investors own 86.65% of the company's stock.

About Revvity

Revvity, Inc NYSE: RVTY is a life sciences and diagnostics company that provides technologies, products and services used in biological research, drug discovery, clinical testing and healthcare. The company serves pharmaceutical and biotechnology companies, academic and government research institutions, hospitals, clinical laboratories and other healthcare organizations.

Its portfolio includes instruments, reagents, consumables, software and related services for areas such as genomics, proteomics, cellular analysis, imaging and multiplex testing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.